 |
|
Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
Soo Han Kim, Eun Jung Jo, Jeongha Mok, Kwangha Lee, Ki Uk Kim, Hye-Kyung Park, Min Ki Lee, Jung Seop Eom, Mi-Hyun Kim
Korean J Intern Med. 2023;38(2):218-225. Published online 2023 Feb 21 DOI: https://doi.org/10.3904/kjim.2022.361
|
|
Citations to this article as recorded by
 A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients
Marie Porte, Adrien Vaudron, Perrine Crequit, Loig Vaugier, Thierry Chatellier, Clémentine Fronteau, Judith Raimbourg, Thomas Goronflot, Jaafar Bennouna, Elvire Pons-Tostivint
Clinical Lung Cancer.2024; 25(2): e101. CrossRef Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis
Laura Bonanno, Lorenzo Calvetti, Alessandro Dal Maso, Alberto Pavan, Loc Carlo Bao, Mattia De Nuzzo, Stefano Frega, Giulia Sartori, Alessandra Ferro, Giulia Pasello, Paolo Morandi, Giuseppe Aprile, Valentina Guarneri
Frontiers in Immunology.2024;[Epub] CrossRef The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
Myeong Geun Choi, Yeon Joo Kim, Jae Cheol Lee, Wonjun Ji, In-Jae Oh, Sung Yong Lee, Seong Hoon Yoon, Shin Yup Lee, Jeong Eun Lee, Eun Young Kim, Chang-Min Choi
Cancer Research and Treatment.2024; 56(2): 422. CrossRef A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy
Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, Nicoletta Jannitti, Antonietta Vitiello, Silvia Carpano, Francesca Fusco, Federico Cappuzzo, Irene Terrenato, Isabella Sperduti, Piera Polidori, Domenico Tarantino, Lidia Di Cerbo, Marcello Pani, Valenti
Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef Comparison of Effectiveness of Programmed Death Protein 1 and Programmed Death Ligand 1 Inhibitors in Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Studies
Nanush Damarpally, Divine Besong Arrey Agbor, Tanya Sinha, Kalyan Naik Gugulothu, Ye Kyaw Myint, Sandipkumar S Chaudhari, Danish Allahwala
Cureus.2024;[Epub] CrossRef Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study
Bertrand Mennecier, Jonathan Khalifa, Renaud Descourt, Laurent Greillier, Charles Naltet, Lionel Falchero
BMC Cancer.2024;[Epub] CrossRef Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer
D. Lamy, P. Mouillot, A. Mariet, R. Barnestein, F. Quilot, C. Fraisse, F. Ghiringhelli, P. Bonniaud, A. Zouak, P. Foucher
Respiratory Medicine and Research.2024; 86: 101125. CrossRef Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis
Yanrong Wang, Lingling Li, Jia Hu, Yan Zhao, Huan Yan, Ming Gao, Xuejiao Yang, Xia Zhang, Junxun Ma, Guanghai Dai
BMC Cancer.2023;[Epub] CrossRef
|